🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 63 of 116

  1. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, CISPLATIN

    Fondazione Telethon ETS

    Patients with non-metastatic muscle invasive bladder cancer

    phase 2 small molecule active

    1 trial

  2. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, GEMCITABINE, IPILIMUMAB, SOTORASIB, ODM-212 5 mg coated tablet, ODM-212 40 mg coated tablet

    Orion Laboratories Pty.

    Neoplasms benign malignant and unspecified (incl. cysts and polyps)

    phase 2 small molecule active

    1 trial

  3. PACLITAXEL ALBUMIN-BOUND, PACLITAXEL , DOCETAXEL , Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion., mRNA-4157, CARBOPLATIN

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  4. PACLITAXEL, Durvalumab_IJB, CARBOPLATIN, Oleclumab_IJB

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 small molecule active

    1 trial

  5. PACLITAXEL, LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. PACLITAXEL, MYCOPHENOLATE MOFETIL, volrustomig, INFLIXIMAB, FLUOROURACIL, CISPLATIN

    AstraZeneca AB

    Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).

    phase 2 small molecule active

    1 trial

  7. PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  8. PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  9. PARACETAMOL, DIPHENHYDRAMINE, INFLIXIMAB, TOCILIZUMAB, AZD7789, EPINEPHRINE

    AstraZeneca AB

    Relapsed/Refractory Classical Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  10. PARP inhibitor 2X-121

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  11. PAXALISIB

    KAZIA THERAPEUTICS LTD

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  12. PBCAR20A

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin's Lymphoma, Relapsed

    phase 2 gene therapy completed

    1 trial

  13. PC14586

    PMV Pharmaceuticals

    Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation

    phase 2 small molecule active

    1 trial

  14. PCAR-019 (anti-CD19 CAR-T cells)

    The First People's Hospital of Lianyungang

    Acute Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  15. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial

  16. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  17. PD 0332991

    Pfizer

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  18. PD-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer Patients

    phase 2 small molecule active

    1 trial

  19. PD-1 Inhibitor plus Chemotherapy

    Sichuan University

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. PD-1 antibody Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancers

    phase 2 small molecule active

    1 trial

  21. PD-1 inhbitor+SHR0302

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. PD-1/CTLA-4 Dual Functional Antibody

    The First People's Hospital of Lianyungang

    Bile Duct Carcinoma

    phase 2 small molecule active

    1 trial

  23. PD-1/PD-L1 inhibitors

    BEONE MEDICINES AUS PTY LTD

    Borderline Resectable Carcinoma

    phase 2 small molecule active

    1 trial

  24. PD-1inhibitor

    Shanghai Chest Hospital

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  25. PD-L1, PD-L2 peptides with Montanide ISA51

    IO Biotech

    Chronic Lymphocytic Leukemia

    phase 2 other completed

    1 trial

  26. PEGENZILEUKIN, Isatuximab, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  27. PEGFILGRASTIM , Rinatabart Sesutecan

    Genmab A/S

    Locally advanced or metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  28. PEGINTERFERON ALFA-2A , TIL cells, Zirconium Zr 89 crefmirlimab berdoxam

    Disc Medicine

    Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  29. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  30. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  31. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  32. PEMBROLIZUMAB

    Pari Pharma GmbH

    Kaposi's sarcoma

    phase 2 small molecule active

    1 trial

  33. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  34. PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB

    Fondazione Telethon ETS

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  35. PEMBROLIZUMAB, DARAXONRASIB (RMC-6236), CARBOPLATIN, DARAXONRASIB (RMC-6236), PEMETREXED, CISPLATIN, RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  36. PEMBROLIZUMAB, OLAPARIB, OLAPARIB

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  37. PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB

    Pfizer Australia Pty Ltd

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  38. PEMETREXED DISODIUM, PACLITAXEL, CARBOPLATIN, CISPLATIN, PACLITAXEL ALBUMIN-BOUND, Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  39. PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, GEN1055 DP, CISPLATIN, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  40. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  41. PF-03446962

    Pfizer

    Carcinoma, Hepatocellular

    phase 2 small molecule terminated

    1 trial

  42. PF-07248144, FULVESTRANT ZENTIVA 250 mg, solution injectable en seringue préremplie, PF-07248144

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  43. PF-07850327 round

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  44. PF-08634404, YERVOY 5 mg/ml concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  45. PHITAH

    Lxo Ireland Designated Activity Company

    Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  46. PI-88

    Biotech Pharmaceutical Co.,

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  47. PI3K inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, T-Cell

    phase 2 small molecule active

    1 trial

  48. PIK3CA inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Neoplasm

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.